2006 Allergan Journal Publications Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: Results from a phase I study in healthy subjects. Authors: Bello Carlo L; Sherman Laurie; Zhou Jihao [AGN]; Verkh Lev; Smeraglia John; Mount Janessa; Klamerus Karen J; Allergan Source: Anti-Cancer Drugs 2006;17(3):353-8 Utility assessment to measure the impact of dry eye disease. Authors: Buchholz Patricia; Steeds Carolyn S; Stern Lee S; Wiederkehr Daniel P; Doyle John J; Katz Laura M; Figueiredo Francisco C; FRCOPH; Allergan Source: Ocul Surf 2006;4(3):155-61 Consequences of glaucoma on circadian and central visual systems Authors: Chiquet C; Drouyer E; Woldemussie E [AGN]; Ruiz G [AGN]; Wheeler L [AGN]; Denis P; Cooper H; Romanet JP; Allergan Source: J Fr Ophthalmol 2006;29(7):847-851 Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium Authors: Corrales RM; Stern ME [AGN]; De Paiva CS; Welch J; Li DQ; Pflugfelder SC; Allergan Source: Invest Ophthalmol Vis Sci 2006;47(8):3293-3302 "Yes "No" or "Yes, but"? Multinomial modelling of NICE decision-making Authors: Dakin HA; Devlin NJ; Odeyemi IAO [AGN]; Allergan Source: Health Policy 2006;77(3):352-367 Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline Authors: De Paiva CS; Corrales RM; Villarreal AL; Farley W; Li DQ; Stern ME [AGN]; Pflugfelder SC; Allergan Source: Invest Ophthalmol Vis Sci 2006;47(7):2847-2856 Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye Authors: De Paiva CS; Corrales RM; Villarreal AL; Farley WJ; Li DQ; Stern ME [AGN]; PfLugfelder SC; Allergan Source: Exp Eye Res 2006;83(3):526-535 A comparison of gatifloxacin to ciprofloxacin in the prophylaxis of Streptococcus pneumoniae in rabbits in a LASIK model Authors: Donnenfeld Robert S; Perry Henry D; Solomon Renee; Jensen Harold G [AGN]; Stein Jonathan; Snyder Robert W; Wittpenn John R; Donnenfeld Eric D; Allergan Source: Eye & Contact Lens 2006 Jan;32(1):46-50 Efficiency of instillation methods for prostaglandin medications. [EMBAL] Authors: Fiscella R; Wilensky JT; Chiang TH; Walt JG [AGN]; Allergan Source: J Ocul Pharmacol Ther 2006;22(6):477-482 Estimated comparative costs of achieving a 20% reduction in intraocular pressure with bimatoprost or latanoprost in patients with glaucoma or ocular hypertension Authors: Fiscella Richard; Walt John [AGN]; Allergan Source: Drugs Aging 2006;23(1):39-47 Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: A US multisite retrospective study Authors: Gieser DK; Williams RT; O'Connell W; Pasquale LR; Rosenthal BP; Walt JG [AGN]; Katz LM; Siegartel LR; Wang LJ; Rosenblatt LC; Stern LS; Doyle JJ; Allergan Source: J Glaucoma 2006;15(5):419-425 Cost considerations in the medical management of glaucoma in the US: Estimated yearly costs and cost effectiveness of bimatoprost compared with other medications Authors: Goldberg Lawrence D; Walt John [AGN]; Allergan Source: PharmacoEconomics 2006;24(3):251-64 Effect of the oestrous cycle, pregnancy and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F-2 alpha and the thromboxane mimetic U46619 Authors: Griffiths AL; Marshall KM; Senior J; Fleming C; Woodward DF [AGN]; Allergan Source: J Endourol 2006;188(3):569-577 The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Authors: Holmstrom Stefan [formerly AGN]; Buchholz Patricia [AGN Germany]; Walt John [AGN]; Wickstrom Source: Curr Med Res Opin 2006;22(5):897-905 Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy) phenyl]-pyrimidine-4- carboxamide: A potent, broad-spectrum state-dependent sodium channel blocker for treating pain states Authors: Ilyin VI; Pomonis JD; Whiteside GT; Harrison JE; Pearson MS; Mark L; Turchin PI; Gottshall S; Carter RB; Nguyen P [AGN]; Hogenkamp DJ; Olanrewaju S; Benjamin E; Woodward RM; Allergan Source: J Pharmacol Exp Ther 2006;318(3):1083-1093 Pharmacokinetics and disposition of memantine in the arterially perfused bovine eye Authors: Koeberle MJ; Hughes PM [AGN]; Skellern GG; Wilson CG; Allergan Source: Pharm Res 2006;23(12):2781-2798 Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost Authors: Komoto Junichi; Yamada Taro; Watanabe Kikuko; Woodward David F [AGN]; Takusagawa Fusao; Allergan Source: Biochemistry 2006 Feb 21;45(7):1987-1996 A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma Authors: Lee PP; Walt JG [AGN]; Doyle JJ; Kotak SV; Evans SJ; Budenz DL; Chen PP; Coleman AL; Feldman RM; Jampel HD; Katz L J; Mills RP; Myers JS; Noecker RJ; Piltz-Seymour JR; Ritch RR; Schacknow PN; Serle JB; Trick GL; Allergan Source: Arch Ophthalmol 2006 Jan;124(1):12-19 A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Authors: Lindblom Bertil; Nordmann Jean-Philippe; Sellem Eric; Chen Enping; Gold R; Polland Werner; Williamson W; Buchholz Patricia [AGN]; Walt John G [AGN]; Groleau Danielle [AGN]; Curry Alistair; Evans Stacy Source: Acta Ophthalmologica Scandinavica 2006;84(1):74-83 Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration Authors: Matias I; Wang JW [AGN]; Morriello AS; Nieves A [AGN]; Woodward DF [AGN]; Di Marzo V; Allergan Source: Prostaglandins Leukot Essent Fatty Acids 2006;75(6):413-418 Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitro. Authors: Matsumoto Steven [AGN]; Way William [AGN]; Tarlo Kirk [AGN]; Short Brian [AGN]; Allergan Source: Cornea 2006;25(9 Suppl 2):S1-S7 Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease Authors: Mills RP; Budenz DL; Lee PP; Noecker RJ; Walt JG [AGN]; Siegartel LR; Evans SJ; Doyle JJ; Allergan Source: Am J Ophthalmol 2006 Jan;141(1):24-30 Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis Authors: Motterle L; Diebold Y; de Salamanca AE; Saez V; Garcia-Vazquez C; Stern ME [AGN]; Calonge M; Leonardi A; Allergan Source: Arch Ophthalmol 2006;124(4):462-468 Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis Authors: Niederkorn JY; Stern ME [AGN]; Pflugfelder SC; De Paiva CS; Corrales RM; Gao J [AGN]; Siemasko K [AGN]; Allergan Source: Immunology 2006 Jan;176:3950-3957 The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey Authors: Nilsson SFE; Drecoll E; Lutjen-Drecoll E; Toris CB; Krauss AHP [AGN]; Kharlamb A [AGN]; Nieves A [AGN]; Guerra T [AGN]; Woodward DF [AGN]; Allergan Source: Invest Ophthalmol Vis Sci 2006;47(9):4042-4049 Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications Authors: Noecker RJ; Walt JG [AGN]; Allergan Source: Am J Ophthalmol 2006 Jan;141(1):S15-S21 Protection of RPE cells from oxidative injury by 15-deoxy-delta12,14- prostaglandin J2 by augmenting GSH and activating MAPK. Authors: Qin Suofu [AGN]; McLaughlin Anne P [AGN]; De Vries Gerald W [AGN]; Allergan Source: Invest Ophthalmol Vis Sci 2006;47(11):5098-105 Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude Authors: Qu XZ; Khutoryanskiy VV; Stewart A; Rahman S; Papahadjopoulos-Sternberg B; Dufes C; McCarthy D; Wilson CG; Lyons R [AGN]; Carter KC; Schatzlein A; Uchegbu IF; Allergan Source: Biomacromolecules 2006;7(12):3452-3459 N-(4-hydroxyphenyl)retinamide induces apoptosis in human retinal pigment epithelial cells: Retinoic acid receptors regulate apoptosis, reactive oxygen species generation, and the expression of heme oxygenase-1 and Gadd153 Authors: Samuel W; Kutty RK; Nagineni S; Vijayasarathy C; Chandraratna RAS [AGN]; Wiggert B; Allergan Source: J Cell Physiol 2006;209(3):854-865 Twice-daily 0.2% brimonidine 0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension. A 12-month randomized trial Authors: Sherwood MB; Craven ER; Chou C [AGN]; DuBiner HB; Batoosingh AL [AGN]; Schiffman RM [AGN]; Whitcup SM [AGN]; Combigan Study Groups I and II; Allergan Source: Arch Ophthalmol 2006;124(9):1230-1238 Evaluation of quality of life for patients with glaucoma Authors: Spaeth G; Walt J [AGN]; Keener J; Allergan Source: Am J Ophthalmol 2006;141:S3-S14 Effects of fourth-generation fluoroquinolones on the ocular surface, epithelium, and wound healing. Authors: Stern ME [AGN]; Gao J [AGN]; Beuerman RW; Farley W; Zhuo L; McDonnell PJ; Pflugfelder SC; Allergan Source: Cornea 2006;25(9 SUPPL.2):S12-S24 Evoked expression of the glutamate transporter GLT-1c in retinal ganglion cells in human glaucoma and in a rat model Authors: Sullivan RKP; WoldeMussie E [AGN]; Macnab L; Ruiz G [AGN]; Pow DV; Allergan Source: Invest Ophthalmol Vis Sci 2006;47(9):3853-3859 Ocular changes after photodynamic therapy Authors: Tzekov Radouil [AGN]; Lin Ton [AGN]; Zhang Kai-Ming [AGN]; Jackson Brittany [AGN]; Oyejide Adelekan [AGN]; Orilla Werhner [AGN]; Kulkarni Amol D [AGN]; Kuppermann Baruch D; Wheeler Larry [AGN]; Burke James [AGN]; Allergan Source: Invest Ophthalmol Vis Sci 2006 Jan;47(1):377-85 Recent advances in ocular therapeutics Authors: Whitcup Scott M [AGN]; Allergan Source: Int Ophthalmol Clin 2006;46(4):1-6 Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data Authors: Wilensky J; Fiscella RG; Carlson AM; Morris LS; Walt J [AGN]; Allergan Source: Am J Ophthalmol 2006;141(1 SUPPL):S28-S33 Potential antinociceptive mechanisms of botulinum toxin. MOGLICHE ANTINOZIZEPTIVE MECHANISMEN VON BOTULINUMTOXIN Authors: Aoki KR [AGN]; Francis J [AGN]; Jost WH; Allergan Source: Schmerz 2006 Sep;20(5):381-7 Using translational medicine to understand clinical differences between botulinum toxin formulations Authors: Aoki KR [AGN]; Ranoux D; Wissel J; Allergan Source: Eur J Neurol 2006;13(Suppl 4):10-19 Understanding the role of botulinum toxin A in the treatment of the overactive bladder-more than just muscle relaxation Authors: Apostolidis A; Haferkamp A; Aoki KR [AGN]; Allergan Source: Eur Urol Suppl 2006;5(11):670-678 The impact of the overactive bladder on health-related utility and quality of life Authors: Currie CJ; McEwan P; Poole CD; Odeyemi IAO [AGN]; Datta SN; Morgan CL; Allergan Source: BJU Int 2006;97(6):1267-1272 The structure and mode of action of different botulinum toxins Authors: Dolly JO; Aoki KR [AGN]; Allergan Source: Eur J Neurol 2006;13(Suppl 4):1-9 A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis Authors: Elkind Arthur H; O'Carroll Philip; Blumenfeld Andrew; DeGryse Ronald [AGN]; Dimitrova Rozalina [AGN]; BoNTA-024-026-036 Study Group; Allergan Source: J Pain 2006;7(10):688-696 Botulinum neurotoxin: From laboratory to bedside Authors: Foster KA; Bigalke H; Aoki KR [AGN]; Allergan Source: Neurotox Res 2006 Apr;9(2-3):133-140 Effectiveness of repeated treatment with botulinum toxin type A across different conditions Authors: Gordon MF; Barron R [AGN]; Allergan Source: South Med J 2006;99(8):853-861 Primary focal hyperhidrosis: Disease characteristics and functional impairment Authors: Hamm H; Naumann MK; Kowalski JW [AGN]; Kutt S; Kozma C; Teale C [AGN]; Allergan Source: Dermatology 2006;212(4):343-353 Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre Authors: Kalsi V; Popat RB; Apostolidis A; Kavia R; Odeyemi IA [AGN]; Dakin HA; Warner J; Elneil S; Fowler CJ; Dasgupta P; Allergan Source: Eur Urol 2006 Mar;49(3):519-27 Two protein trafficking processes at motor nerve endings unveiled by botulinum neurotoxin E Authors: Lawrence G; Wang J; Kwo Chion CKN; Aoki RK [AGN]; Dolly OJ; Allergan Source: J Pharmacol Exp Ther 2006;320(1):410-18 Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies Authors: Maruta T; Dolimbek BZ; Aoki KR [AGN]; Atassi MZ; Allergan Source: J Neurosci Methods 2006;151(2):90-96 Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care Authors: Odeyemi AO [AGN]; Dakin HA; O'Donnel RA; Warner J; Jacobs A; Dasgupta P; Allergan Source: Int J Clin Pract 2006 Aug;60(8):949-58 Botulinum toxin type A in the prophylactic treatment of chronic tension- type headache: A multicentre, double-blind, randomized, placebo- controlled, parallel-group study Authors: Silberstein SD; Gobel H; Jensen R; Elkind AH; DeGryse R [AGN]; Walcott JMCM [AGN]; Turkel C [AGN]; Allergan Source: Cephalalgia 2006;26(7):790-800 Developing patient-reported outcome measures for pain clinical trials: IMMPACT recommendations Authors: Turk DC; Dworkin RH; Burke LB; Gershon R; Rothman M; Scott J; Allen RR; Atkinson JH; Chandler J; Cleeland C; Cowan P; Dimitrova R [AGN]; Dionne R; Farrar JT; Haythornthwaite JA; Hertz S; Jadad AR; Jensen MP; Kellstein D; Kerns RD; Manning DC; Martin S; Max MB; McDermott MP; McGrath P; Moulin DE; Nurmikko T; Quessy S; Raja S; Rappaport BA; Rauschkolb C; Robinson JP; Royal MA; Simon L; Stauffer JW; Stucki G; Tollett J; von Stein T; Wallace MS; Wernicke J; White RE; Williams AC; Witter J; Wyrwich KW; Allergan Source: Pain 2006;125(3):208-215 Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity Authors: Turkel Catherine C [AGN]; Bowen Beta [AGN]; Liu Jingyu [AGN]; Brin Mitchell F [AGN]; Allergan Source: Arch Phys Med Rehabil 2006 Jun;87(6):786-92
Stan Douglas Born 1960, Vancouver. Lives and works in Vancouver, British Columbia, Canada. EDUCATION 1982 Emily Carr College of Art, Vancouver, British Columbia, Canada SOLO EXHIBITIONS 2009 Stan Douglas: Klatsassin , Mongin Art Center, Seoul, Korea [brochure] Stan Douglas: Klatsassin , Vancouver Art Gallery, Vancouver, British Columbia, Canada 2008 Stan Douglas: Humor, Irony a
The medication Haldol is a typical neuroleptic. It is used to treat psychosis. Psychosis can be experienced as disorganized thinking or behavior and unusual perceptions (hearing voices, seeing things, feeling paranoid). Haldol is also used to treat other clinical situations such as tics and stuttering or extreme mood instability. Generally these symptoms interfere with your life goals. Hald